Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 7, 2006 - Issue 1
Submit an article Journal homepage
342
Views
15
CrossRef citations to date
0
Altmetric
Drug Evaluation

Tacrolimus in rheumatoid arthritis

Roy Fleischmann Clinical Professor of Medicine, University of Texas Southwestern Medical Centre at Dallas, USA; Co-Medical Director, Radiant Research – Dallas, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235-5360, USA. [email protected]
,
Imran Iqbal Rheumatology Associates, St. Paul University Hospital, USA
&
Richard L Stern Clinical Assistant Professor of Medicine, University of Texas Southwestern Medical Centre at Dallas, USA; Radiant Research – Dallas,5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235-5360, USA
Pages 91-98 | Published online: 22 Dec 2005

Bibliography

  • O’DELL JR: Rheumatoid arthritis: the clinical picture. In: Arthritis and Allied Conditions. WJ Koopman (Ed). Lippincott Williams & Wilkins, Philadelphia, USA (2001):1153-1186.
  • CHEHATA JC, HASSELL AB, CLARKE SA et al.: Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (2001) 40(4):447-452.
  • GABRIEL SE, CROWSON CS, KREMERS HM et al.: Survival in rheumatoid arthritis: a population- based analysis of trends over 40 years. Arthritis Rheum. (2003) 48(1):54-58.
  • YOUNG A, DIXEY J, KULINSKAYA E et al.: Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis. (2002) 61(4):335-340.
  • CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344(12):907-916.
  • VAN RIJTHOVEN AW, DIJKMANS BA, THE HS et al.: Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. J. Rheumatol. (1991) 18(6):815-820.
  • WELLS G, HAGUENAUER D, SHEA B et al.: Cyclosporine for rheumatoid arthritis. Cochrane. Database. Syst. Rev. (2000) 2:CD001083.
  • TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. (1995) 333(3):137-141.
  • SAWADA S, SUZUKI G, KAWASE Y, TAKAKU F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. (1987) 139(6):1797-1803.
  • FLEISCHMANN R: Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert. Opin. Drug Saf. (2003) 2(4):347-365.
  • FLEISCHMANN RM, IQBAL I, STERN RL: Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert. Opin. Drug Saf. (2004) 3(5):391-403.
  • STAATZ CE, TETT SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. (2004) 43(10):623-653.
  • Fujisawa Healthcare, Inc.: Prograf® (tacrolimus) prescribing information. Deerfield, IL, USA (2005).
  • MIYATA S, OHKUBO Y, MUTOH S: A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm. Res. (2005) 54(1):1-9.
  • TOCCI MJ, MATKOVICH DA, COLLIER KA et al.: The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. (1989) 143(2):718-726.
  • SAWADA S, SUZUKI G, KAWASE Y, TAKAKU F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. (1987) 139(6):1797-1803.
  • SUGIYAMA E, SUZUKI H, TUNRU IS et al.: FK506, an immunosuppressant, partially inhibits interleukin 6 production by adherent rheumatoid synovial cells. J. Rheumatol. (1994) 21(9):1597-1601.
  • SAKUMA S, KATO Y, NISHIGAKI F et al.: FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br. J. Pharmacol. (2000) 130(7):1655-1663.
  • FUSELER JW, HEARTH-HOLMES M, GRISHAM MB et al.: FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis. J. Rheumatol. (2000) 27(1):190-199.
  • MAGARI K, NISHIGAKI F, SASAKAWA T et al.: Anti-arthritic properties of FK506 on collagen-induced arthritis in rats. Inflamm. Res. (2003) 52(12):524-529.
  • SAKUMA S, NISHIGAKI F, MAGARI K et al.: FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm. Res. (2001) 50(10):509-514.
  • MAGARI K, MIYATA S, NISHIGAKI F, OHKUBO Y, MUTOH S: Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflamm. Res. (2004) 53(10):544-550.
  • MAGARI K, MIYATA S, OHKUBO Y, MUTOH S, GOTO T: Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant- induced arthritis. Br. J. Pharmacol. (2003) 139(5):927-934.
  • WALLEMACQ PE, VERBEECK RK: Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin. Pharmacokinet. (2001) 40(4):283-295.
  • HOLUM MB, WISEMANDLE W, BEKERSKY I: Concomitant tacrolimus (TAC) and methotrexate(MTX) pharmacokinetics (PK) in rheumatoid arthritis (RA) patients. J. Clin. Pharmacol. (2002) 42:1053.
  • GREMILLION RB, POSEVER JO, MANEK N, WEST JP, VAN VOLEN-HOVEN RF: Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J. Rheumatol. (1999) 26(11):2332-2336.
  • FURST DE, SAAG K, FLEISCHMANN MR et al.: Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. (2002) 46(8):2020-2028.
  • FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38(6):727-735.
  • KONDO H, ABE T, HASHIMOTO H et al.: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J. Rheumatol. (2004) 31(2):243-251.
  • YOCUM DE, FURST DE, KAINE JL et al.: Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. (2003) 48(12):3328-3337.
  • PARKER CT, RENNIE T: Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. Arthritis Rheum. (2004) 50(9):3051-3052.
  • KREMER JM, HABROS JS, KOLBA KS et al.: Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. (2003) 48(10):2763-2768.
  • YOCUM DE, FURST DE, BENSEN WG et al.: Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (2004) 43(8):992-999.
  • STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. (1999) 159(21):2542-2550.
  • MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130(6):478-486.
  • ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. (1993) 36(12):1681-1690.
  • VAN DE PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. (2004) 63(5):508-516.
  • KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (2002) 137(9):726-733.
  • WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340(4):253-259.
  • MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354(9194):1932-1939.
  • KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50(5):1400-1411.

Website

  • http://www.hopkins-arthritis.som.jhmi.edu/edu/acr/acr.html#ra_trials Explanation of the American College of Rheumatology definition of improvement in rheumatoid arthritis trials.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.